Literature DB >> 26658959

Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.

Jordan D Lane1, Mark W Friedberg2, Charles L Bennett3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26658959      PMCID： PMC4842308          DOI： 10.1001/jamaoncol.2015.3928

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Pharmacoeconomic analyses: making them transparent, making them credible.

Authors:  D Rennie; H S Luft
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

2.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 3.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506
  3 in total
  3 in total

Review 1.  Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.

Authors:  Scott F Huntington
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Industry sponsorship bias in cost effectiveness analysis: registry based analysis.

Authors:  Feng Xie; Ting Zhou
Journal:  BMJ       Date:  2022-06-22

3.  Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.

Authors:  Alyson Haslam; Mark P Lythgoe; Emma Greenstreet Akman; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2021-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.